Concomitant pharmacotherapy among youths treated in routine psychiatric practice.

OBJECTIVES The aim of this study was to assess rates and correlates of concomitant pharmacotherapy in children and adolescents treated by psychiatrists in a broad range of clinical settings. METHODS Cross-sectional data on 392 child and adolescent patients aged 2-17 years from the 1997 and 1999 American Psychiatric Practice Research Network Study of Psychiatric Patients and Treatments were used, and weighted estimates are provided. RESULTS Findings indicate that 84% of child and adolescent patients received one or more psychopharmacologic medications; 52% of patients treated with medications received concomitant pharmacotherapy (i.e., two or more medications). Patients who were treated with psychopharmacologic treatments received a median of 2 medications (range, 1-6). Highest rates of concomitant pharmacotherapy were among patients with bipolar disorder (87%). Correlates of concomitant pharmacotherapy included: (1) having a diagnosis of bipolar disorder, (2) having co-occurring Axis I or II disorders or general medical conditions, and (3) currently receiving treatment in an inpatient setting. CONCLUSIONS Over 40% of child and adolescent patients of psychiatrists were prescribed two or more psychopharmacologic medications. Patients with chronic and clinically complex conditions were more likely to receive concomitant pharmacotherapy. Most often, efficacy of U.S. Food and Drug Administration (FDA)-approved medications has been examined as monotherapy, and cautions on drug interactions and off-label use derived from multiple sources accompany each product. With high rates of concomitant pharmacotherapy among children and adolescents in psychiatric care, additional research on efficacy and safety of this treatment strategy is necessary.

[1]  M. Lambert,et al.  Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon , 2003 .

[2]  M. Olfson,et al.  National trends in the treatment of attention deficit hyperactivity disorder. , 2003, The American journal of psychiatry.

[3]  D. Safer,et al.  Concomitant psychotropic medication for youths. , 2003, The American journal of psychiatry.

[4]  Andrés Martin,et al.  Datapoints: use of multiple psychotropic drugs by Medicaid-insured and privately insured children. , 2002, Psychiatric services.

[5]  M. Weissman,et al.  National trends in the use of psychotropic medications by children. , 2002, Journal of the American Academy of Child and Adolescent Psychiatry.

[6]  F. Lynch,et al.  Rising prevalence of antidepressants among US youths. , 2002, Pediatrics.

[7]  S. Marcus,et al.  Prescription of antipsychotic drugs by office-based physicians in the United States, 1989-1997. , 2002, Psychiatric services.

[8]  B. Vitiello,et al.  Datapoints: trends in combined pharmacotherapy with stimulants for children. , 2002, Psychiatric services.

[9]  G. Simpson,et al.  Psychopharmacology: rational and irrational polypharmacy. , 2001, Psychiatric services.

[10]  M. Olfson,et al.  Prescription of psychotropic medications to youths in office-based practice. , 2001, Psychiatric services.

[11]  J. McClellan,et al.  Aacap Official ActionPractice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia , 2001 .

[12]  J. Rushton,et al.  Pediatric stimulant and selective serotonin reuptake inhibitor prescription trends: 1992 to 1998. , 2001, Archives of pediatrics & adolescent medicine.

[13]  F. Lynch,et al.  Trends in the prescribing of psychotropic medications to preschoolers. , 2000, JAMA.

[14]  I. Choonara,et al.  Adverse drug reactions to unlicensed and off‐label drugs on paediatric wards: a prospective study , 1999, Acta paediatrica.

[15]  N. Ryan,et al.  Mood stabilizers in children and adolescents. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[16]  L. Burke,et al.  Psychoactive medication prescribing practices for U.S. children: gaps between research and clinical practice. , 1999, Journal of the American Academy of Child and Adolescent Psychiatry.

[17]  R. Kessler,et al.  Psychiatric patients and treatments in 1997: findings from the American Psychiatric Practice Research Network. , 1999, Archives of general psychiatry.

[18]  H. Pincus,et al.  Clinical and treatment characteristics of children with attention-deficit/hyperactivity disorder in psychiatric practice. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[19]  B. Birmaher,et al.  Practice Parameters for the Assessment and Treatment of Children and Adolescents With Depressive Disorders , 1998 .

[20]  T. Belin,et al.  Variations in ADHD treatment among special education students. , 1998, Journal of the American Academy of Child and Adolescent Psychiatry.

[21]  B. Vitiello.  Pediatric Psychopharmacology and the Interaction between Drugs and the Developing Brain , 1998, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[22]  H. Pincus,et al.  Characterizing psychiatry with findings from the 1996 National Survey of Psychiatric Practice. , 1998, The American journal of psychiatry.

[23]  J. McClellan,et al.  Practice parameters for the assessment and treatment of children and adolescents with bipolar disorder. American Academy of Child and Adolescent Psychiatry. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[24]  M. Dulcan,et al.  Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[25]  D. Connor,et al.  Combined pharmacotherapy in children and adolescents in a residential treatment center. , 1997, Journal of the American Academy of Child and Adolescent Psychiatry.

[26]  D. Safer,et al.  Increased methylphenidate usage for attention deficit disorder in the 1990s. , 1996, Pediatrics.

[27]  M. Olfson,et al.  Outpatient mental health care in nonhospital settings: distribution of patients across provider groups. , 1996, The American journal of psychiatry.

[28]  M. Nichol,et al.  Factors predicting the use of multiple psychotropic medications. , 1995, The Journal of clinical psychiatry.

[29]  G. Klerman,et al.  Trends in the prescription of psychotropic medications. The role of physician specialty. , 1993, Medical care.

[30]  M. A. Epstein,et al.  The Boundaries of Attention Deficit Disorder , 1991, Journal of learning disabilities.

[31]  L. M. Lucas,et al.  Polypharmacy , 2007, Journal of General Internal Medicine.

[32]  L. Magder,et al.  Psychotropic practice patterns for youth: a 10-year perspective. , 2003, Archives of pediatrics & adolescent medicine.

[33]  E. Leibenluft,et al.  Medication use in children and adolescents treated in the community for bipolar disorder. , 2003, Journal of child and adolescent psychopharmacology.

[34]  Andrés Martin,et al.  Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. , 2003, Psychiatric services.

[35]  D. Safer,et al.  Sources of data for pharmacoepidemiological studies of child and adolescent psychiatric disorders. , 1997, Journal of child and adolescent psychopharmacology.

[36]  K. Gadow.  An overview of three decades of research in pediatric psychopharmacoepidemiology. , 1997, Journal of child and adolescent psychopharmacology.

[37]  R. Dufresne.  Issues in polypharmacotherapy: focus on major depression. , 1996, Psychopharmacology bulletin.

[38]  J. Strayhorn.  The Case of the Passionate Couple , 1995 .